Publications by authors named "Johannes Foersch"
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Cardiovasc Diabetol
August 2023
Article Synopsis
- - The study compares cardiovascular risks in patients with type 2 diabetes who started either empagliflozin or dipeptidyl peptidase-4 inhibitors (DPP-4i) across Europe and Asia, focusing on those with and without prior cardiovascular disease (CVD) or heart failure (HF).
- - Using data from over 85,000 matched patients and advanced statistical methods, the research found that empagliflozin users had a significantly lower risk of hospitalizations for heart failure, cardiovascular mortality, and strokes compared to DPP-4i users.
- - Overall, the findings indicate that empagliflozin offers protective cardiovascular benefits in diverse populations, regardless of their history of heart disease or heart
Background: This study describes real-world treatment-related outcomes and healthcare costs of German type 2 diabetes mellitus (T2D) patients who initiated insulin therapy.
Methods: This retrospective analysis includes German claims data from 01/01/2012 until 31/12/2016. Identification of eligible patients took place between 01/01/2013 and 31/12/2015, allowing for at least 1 year of follow-up.
Introduction: Empagliflozin reduced morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) in clinical trials. A registry study was undertaken to describe evolution of patient characteristics and assess the real-world effectiveness/safety of empagliflozin.
Research Design And Methods: Data from the Diabetes Patienten Verlaufsdokumentation (DPV)/Diabetes Versorgungsevaluation (DIVE) registries on 9571 adults with T2DM (registered in 2014-2019) receiving empagliflozin were used.
Background: A substantial share of type 2 diabetes mellitus (T2DM) patients receive insulin. However, little is known about the real-world treatment patterns around insulin initiation.
Methods: This was a retrospective claims data analysis.
Aim: Optimal treatment intensification strategies in patients with type-2 diabetes mellitus (T2DM) receiving basal insulin supported oral antidiabetic therapy (BOT) remain controversial. The objective of the present study was to compare outcomes of BOT-intensification by either the uptitration of long-acting insulin glargine or by the immediate addition of a rapid acting insulin analogue (RAIA).
Methods: This was a prospective, observational, 24-week study in T2DM patients with BOT using insulin glargine and baseline glycated hemoglobin (HbA1c) between 7.
Objective: To determine whether daily intake of 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] is safe and improves beta-cell function in patients with recently diagnosed type 1 diabetes.
Research Design And Methods: Safety was assessed in an open study of 25 patients aged 18-39 years with recent-onset type 1 diabetes who received 0.25 microg 1,25(OH)(2)D(3) daily for 9 months.